Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Bruckert, E.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Bruckert, E.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The European Society of Cardiology 2005. All rights reserved. For Permissions, please e-mail: journals.permissions@oxfordjournals.org

Impact of lipid treatment on cardiovascular risk reduction: new therapeutic targets

Eric Bruckert*

Prevention of Cardiovascular Disease Center, Department of Endocrinology and Metabolism, Pitié-Salpêtrière Hospital, Paris, France

* Corresponding author. E-mail address: eric.bruckert{at}psl.ap-hop-paris.fr

High levels of LDL cholesterol (LDL-c) are causally related to the development of atherosclerosis. A large body of epidemiological evidence supports a direct relationship between the level of serum LDL-c and the risk of cardiovascular disease, and clinical trials have shown that lowering LDL-c with statins leads to a 30% decrease in the risk of cardiovascular events. However, many patients taking statins continue to suffer cardiovascular disease, highlighting the need both to improve the number of patients reaching LDL-c therapeutic goals and to develop new therapeutic targets. The apoB/apoA-I ratio has been shown to be a major contributor to the risk of myocardial infarction and hence increasing HDL-cholesterol (HDL-c) offers a promising approach to further decrease cardiovascular risk. Clinical trial data with fibrates and nicotinic acid, together with preliminary data on potent new treatments, support HDL-c as a therapeutic target. The cardioprotective effect of HDL-c may not solely be related to its role in reverse cholesterol transport.

Key Words: Fibrates • CETP inhibitor • Cholesterol • HDL-cholesterol • HDLc mimetic • Lipids • Nicotinic acid • Obesity


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.